179 related articles for article (PubMed ID: 23639045)
1. Lenalidomide at therapeutic and supratherapeutic doses does not prolong QTc intervals in the thorough QTc study conducted in healthy men.
Chen N; Ye Y; Liu L; Reyes J; Assaf MS; Kasserra C; Zhou S; Palmisano M
Basic Clin Pharmacol Toxicol; 2013 Sep; 113(3):179-86. PubMed ID: 23639045
[TBL] [Abstract][Full Text] [Related]
2. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
de Kam PJ; van Kuijk J; Prohn M; Thomsen T; Peeters P
Clin Drug Investig; 2010; 30(9):599-611. PubMed ID: 20568829
[TBL] [Abstract][Full Text] [Related]
3. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
Davis JD; Hackman F; Layton G; Higgins T; Sudworth D; Weissgerber G
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):68-75. PubMed ID: 18333868
[TBL] [Abstract][Full Text] [Related]
4. Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers.
Taubel J; Naseem A; Harada T; Wang D; Arezina R; Lorch U; Camm AJ
Br J Clin Pharmacol; 2010 Apr; 69(4):391-400. PubMed ID: 20406223
[TBL] [Abstract][Full Text] [Related]
5. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
[TBL] [Abstract][Full Text] [Related]
6. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
Abbas R; Hug BA; Leister C; Sonnichsen D
Int J Cancer; 2012 Aug; 131(3):E304-11. PubMed ID: 22065400
[TBL] [Abstract][Full Text] [Related]
7. Lomitapide at supratherapeutic plasma levels does not prolong the Qtc interval--results from a TQT study with moxifloxacin and ketoconazole.
Darpo B; Ferber G; Zhou M; Sumeray M; Sager P
Ann Noninvasive Electrocardiol; 2013 Nov; 18(6):577-89. PubMed ID: 24118671
[TBL] [Abstract][Full Text] [Related]
8. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
9. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
[TBL] [Abstract][Full Text] [Related]
10. Effects of three fluoroquinolones on QT interval in healthy adults after single doses.
Noel GJ; Natarajan J; Chien S; Hunt TL; Goodman DB; Abels R
Clin Pharmacol Ther; 2003 Apr; 73(4):292-303. PubMed ID: 12709719
[TBL] [Abstract][Full Text] [Related]
11. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
Harris SC; Morganroth J; Ripa SR; Thorn MD; Colucci S
Postgrad Med; 2017 Jan; 129(1):69-80. PubMed ID: 27927048
[TBL] [Abstract][Full Text] [Related]
12. A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults.
Boni JP; Leister C; Hug B; Burns J; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1433-42. PubMed ID: 22367193
[TBL] [Abstract][Full Text] [Related]
13. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
Darpö B; Sager P; MacConell L; Cirincione B; Mitchell M; Han J; Huang W; Malloy J; Schulteis C; Shen L; Porter L
Br J Clin Pharmacol; 2013 Apr; 75(4):979-89. PubMed ID: 22882281
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects.
Matthys G; Park JW; McGuire S; Wire MB; Zhang J; Bowen C; Williams D; Jenkins JM; Peng B
Br J Clin Pharmacol; 2010 Jul; 70(1):24-33. PubMed ID: 20642544
[TBL] [Abstract][Full Text] [Related]
15. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
German P; Mathias A; Brainard DM; Song Q; Ling J; Kearney BP
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):641-651. PubMed ID: 29058821
[TBL] [Abstract][Full Text] [Related]
16. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
[TBL] [Abstract][Full Text] [Related]
17. Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects.
Dixon R; Job S; Oliver R; Tompson D; Wright JG; Maltby K; Lorch U; Taubel J
Br J Clin Pharmacol; 2008 Sep; 66(3):396-404. PubMed ID: 18662287
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox does not induce QT/QTc-prolongation in healthy subjects.
Sechaud R; Dumortier T; Balez S
Int J Clin Pharmacol Ther; 2009 May; 47(5):321-7. PubMed ID: 19473594
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects.
Marbury TC; Jin B; Panebianco D; Murphy MG; Sun H; Evans JK; Han TH; Constanzer ML; Dru J; Shadle CR
Anesth Analg; 2009 Aug; 109(2):418-25. PubMed ID: 19608812
[TBL] [Abstract][Full Text] [Related]
20. Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study.
Shen Z; Gillen M; Tieu K; Nguyen M; Harmon E; Wilson DM; Kerr B; Lee CA
Drug Des Devel Ther; 2016; 10():3509-3517. PubMed ID: 27826183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
